Drug intelligence / Profile preview

AX-004

Development stage: Preclinical
Lead developer: Axelyf
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

AX-004 is an mRNA-based therapeutic candidate developed by Axelyf, utilizing lipid nanoparticle (LNP) delivery technology. It is currently undergoing IND-enabling studies for the treatment of an undisclosed autoimmune disease. The company aims to progress the candidate toward clinical development, with IND-enabling milestones targeted for 2027. AX-004 leverages Axelyf's expertise in RNA therapeutics and LNP delivery to address unmet needs in the autoimmune space.

Beyond the preview

Go deeper on AX-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AX-004.

Explore the full profile